Thus, Ezrin, AKAP95, and Yotiao may represent future therapeutic targets for inhibiting bronchial EMT in COPD, possibly in combination with already existing therapies, such as β2-agonists and PDE4 inhibitors. This evidence concerns the gene PDE4A and chronic obstructive pulmonary disease.